Parkinson's Disease Substantia

Parkinson disease (PD) is one of the most common neurologic disorders. and it affects approximately 1% of individuals older than 60 years old. Parkinson’s disease is a condition that progresses slowly by treatment. In addition, loss of pigmented dopaminergic neurons of the substantianigra pars compacta and the presence of Lewy bodies and Lewyneurites are the two major neuropathologic findings in Parkinson disease (Hauser, 2016).

Parkinson 's disease is a progressive neurologic degenerative disease of the Central Nervous system. The brain produces Dopamine and Norepinephrine, which are chemicals needed for smooth muscle movement and coordination, heart rate, and blood pressure. Dopamine and Norepinephrine are released by basal ganglions that are produced in a bundle of nerve cells in the brainstem called substantia nigra. In Parkinson 's patients, the substantia nigra are destroyed and neither of the chemicals can be released into the body. (3) The decrease in Norepinephrine causes heart arrhythmia and low blood pressure, causing the person to get dizzy upon standing or tire easily. The lack of Dopamine, the smooth muscle movement and coordination controller is now gone, or significantly decreased, resulting in the first signs of Parkinson’s disease, pill-rolling, a one handed tremor and a decreased appetite. (2)

36. _ Dementia__ is a general term used to describe a permanent or progressive organic mental disorder. A common form of this disorder seen in individuals older than 60 years of age is _Alzheimer's Disease_ disease.

Parkinson’s disease is a “neurodegenerative disorder of the basal nuclei due to insufficient secretion of the neurotransmitter dopamine” (Marieb & Hoehn, 2013, p. G-17). The cause of Parkinson’s disease is unknown, but many factors play a role in the development of Parkinson’s disease. One factor that has been found in an individual who has Parkinson’s disease causes over activity of targeted dopamine-deprived basal nuclei. This over activity is caused by the breakdown of neurons that release dopamine in the substantia nigra (Marieb & Hoehn, 2013). Another factor that is present in a person who has Parkinson’s disease, is the presence of lewy bodies in the brain stem ("What is lbd?," 2014). Lewy bodies are unusual

James Parkinson first described the disease named after him as a motor dysfunction through an essay on “shaking palsy” in the early nineteenth century, with Friedrich Lewy a century later describing atypical masses of protein (now known as Lewy bodies) within cell cytoplasm’s in the brainstems of those displaying symptoms of Parkinson’s disease including those with dementia. Because of the distinct similarities, there has been professional discussion that Parkinson’s disease, Parkinson’s with dementia, and dementia with Lewy bodies be grouped as one: Lewy Body Disease (Auning, E., A., & Aarsland, D., 2012, p. 233). Dementia associated with Parkinson’s is frequent, with the occurrence assessed. Those with Parkinson’s disease with dementia represent 5% of all people who have dementia, and of

PD is the second most common neurodegenerative disease featured pathologically by the progressive loss of dopaminergic neurons in the substantia nigra. The typical symptoms of PD include slowness of movements (bradykinesia), muscle stiffness (rigidity), tremor, and balance disturbance. Etiopathologically, PD is considered to be caused by the significant loss of dopaminergic neurons in the substantia nigra pars compacta and the subsequent dopamine depletion at the striatum. To date, there are only symptomatic treatments available for PD, particularly in the early stages of the disease. No therapy has been found that can cure or halt the progression of the disease.

These deficits increase during the course of the disease and are due to loss of dopamine-secreting neurons in the motor circuits in the basal ganglia which are necessary for control and coordination of movements. The symptoms displayed because of this are: bradykinesia, resting tremor, rigidity of muscles and impaired posture (Millage, Vesey, Finkelstein, & Anheluk, 2017). Research indicates that exercise modalities can improve both motor and non-motor aspects of PD (Dashtipour et al., 2015).

Parkinson’s is a progressive neurodegenerative disease, primarily affecting voluntary, precise, and controlled movement. Parkinson’s occurs when cells in a part of the brain called the substantia nigra die off. These cells are responsible for producing dopamine. With less and less dopamine, a person has less and less ability to regulate their movements, body and emotions. The terms "familial Parkinson's disease" and "sporadic Parkinson's disease" are used to differentiate genetic from truly idiopathic forms of the disease.

Dopamine is a brain chemical/Neurotransmitter that work as messenger signal between the Substantia Nigra to the next relay station of the brain, the corpus striatum which helps to produce smooth coordinate movement and also plays a major role to help control muscle’s movement. With Parkinson’s disease, the brain cells that produce dopamine slowly die, which lead to decrease production of Dopamine. The loss of dopamine causes abnormal nerve firing with brain and the cells that control muscle’s movement by sending the messages to the muscles; due to this it becomes really hard to control muscles movement and cause tremors and various other symptoms such as rigidity and difficulty walking and performing daily tasks. Dopamine is not the only neurotransmitter involved in Parkinson’s Disease. Norepinephrine is very relatively close to dopamine and is also involved in Parkinson’s Disease. Individuals with Parkinson’s Disease have loss of nerve ending that produce norepinephrine. Norepinephrine is a major neurotransmitter for sympathetic nervous system, which control many autonomic functions of our body; it causes increase in blood pressure and heart rate. Loss of norepinephrine can help us explain the non-motor symptoms associated with Parkinson’s Disease such as fatigue, decrease in gastric stability and disruption in cognition. Parkinson’s Disease can be hereditary

An important finding in past decades is that Parkinson’s disease (PD) is not just a disease of dopaminergic neurons in the substantia nigra pars compacta (SNpc). Significant neuronal loss (≈80%) in the locus coerueus (LC) occurs in PD. Neurodegenerration of LC neurons starts earlier with a greater magnitude than that in the SNpc. Evidence to support this pathogenesis in PD also includes: 1) Lewy bodies, a typical pathologic alteration of PD, accumulate with a greater extent in the LC before their appearance in the SNpc. 2) The non-motor symptoms, closely correlated with loss of LC neurons, often occur many years before the onset of motor dysfunction. 3) Animal PD models showed an earlier loss of LC neurons than the SNpc. Together, these

Parkinson’s disease is affected by the degeneration of dopaminergic neurons which is responsible to produce dopamine. Dopaminergic neurons have their cell bodies in substantia nigra pars compacta (SNpc) in basal ganglia (O’Sullivan and Schmitz, 2007). Basal ganglia are a collection of interconnected gray matter nuclear masses deep within the brain”. These gray matter masses are caudate, putamen, globus pallidus, subthalamic nucleus and the substantia nigra. Basal ganglia receive its input through striatum (O’Sullivan and Schmitz, 2007).

Parkinson’s disease is a neurodegenerative disorder characterized by motor symptoms or tremors, rigidity, (bradykinesia) or slowness of movement and posture instability. Parkinson’s involves the malfunction and death of vital nerve cells in the brain. This disease primarily affects neurons in area of the brain called substantia nigra. Some of these dying neurons produce dopamine a chemical that sends messages to the part of the brain that controls movement and coordination. The symptoms of Parkinson’s disease usually begin on one side of the body and within time spread to both sides of the body. The primary process that causes Parkinson’s disease signs and symptoms is when dopamine producing nerve cells in the brain die prematurely. Dopamine is one of the main neurotransmitters in the brain. In a healthy brain, ample dopamine is produced so that the brain cells can coordinate smooth and precise muscle movements. However, when dopamine cells are lost, brain cells communicate abnormally with muscles, which can lead to impaired body movement. (Null, 2013, pp. 153-176)

Parkinson disease (PD) is a progressive neurodegenerative disorder characterized mainly by physical and psychological disabilities. This disorder was named after James Parkinson, an English physician who first described it as shaking palsy in 1817 (Goetz, Factr, and Weiner, 2002). Jean- Martin Charcot, who was a French neurologist, then progressed and further refined the description of the disease and identified other clinical features of PD (Goetz, Factr, and Weiner, 2002). PD involves the loss of cells that produce the neurotransmitter dopamine in a part of the brain stem called the substansia nigra, which results in several signs and symptoms (Byrd, Marks, and Starr, 2000). It is manifested clinically by tremor,

Rationale: Parkinson’s disease is caused by the degeneration of nerves responsible for the production of the dopamine (inhibitory neurotransmitter) within the basal ganglia inside the substantia nigra. Nerve fibers that connect the corpus striatum and substantia nigra are responsible for complex body movements, such unconscious movement, control of position, and posture by the balancing of acetylcholine (excitatory), and dopamine (inhibitory). The loss of dopamine creates an imbalance and causing the manifestations of Parkinson’s disease (Karch, 2013).

The origin of the impairments of PD disease start in the basal ganglia, the basal ganglia in laymen terms would be defined as the basic cluster of nuclei, located